ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Judge Declines To Block NCI Contract Award

February 24, 1995

Guideline Revisions or Outstanding Investigator Grant Still Controversial

December 9, 1983

Oxaliplatin Added To 5-FU/LV Improves Disease-Free Survival In Early Colon Cancer

June 24, 2005

New Edition Of Book On Cancer Rates, Risks, Available

February 28, 1997

In Aftermath of NEJM Article, Critic Bailar Declares The Defeat Of Cancer Treatment

June 6, 1997

Brain tumor foundations form collaboration.

July 15, 2005